Dutch Study Highlights Benefits of Off-Label Targeted Cancer Therapies for Patients
A Dutch study has revealed that off-label targeted cancer therapies can significantly benefit patients, as demonstrated in the Dutch multicenter DRUP trial. This trial, which included over 1600 patients, aimed to expand the use of existing drugs beyond their approved indications to provide more personalized treatment options. The results, published in Nature, show that about one-third of the participants responded positively to the treatment or maintained stable disease for at least four months. The trial also identified 67 exceptional responders who showed complete response or remained progression-free for at least two years. The study underscores the potential of these targeted drugs to deliver substantial benefits, even for heavily pretreated, difficult-to-treat, or rare cancers. 
